Idevax
Idevax develops and commercializes a medical device for standardized intradermal injections. The company focuses on enabling reliable skin drug delivery and dose-sparing vaccination strategies through device design, preclinical evaluation, regulatory conformity (CE Class IIa, ISO 13485), and scientific communication. Activities include preclinical testing, participation in clinical and veterinary use discussions, white papers, trial-kit distribution, and collaborative projects.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Products
VAX-ID (intradermal injection device)
A needle-adaptor device engineered to deliver controlled intradermal injections compatible with liquid-formulated vaccines; designed for standardized, reproducible intradermal administration with limited insertion depth intended to minimize pain.
VAX-ID (intradermal injection device)
A needle-adaptor device engineered to deliver controlled intradermal injections compatible with liquid-formulated vaccines; designed for standardized, reproducible intradermal administration with limited insertion depth intended to minimize pain.
Services
Supply of trial kits to allow external evaluation of intradermal injection devices.
Collaboration with research organizations, industry partners, and consortia to evaluate and deploy intradermal delivery solutions in public-health and therapeutic contexts.
Supply of trial kits to allow external evaluation of intradermal injection devices.
Collaboration with research organizations, industry partners, and consortia to evaluate and deploy intradermal delivery solutions in public-health and therapeutic contexts.
Expertise Areas
- Intradermal vaccine delivery
- Medical device design for injection systems
- Preclinical safety and performance testing
- Dose-sparing vaccination strategies
Key Technologies
- Intradermal injection adapters (needle-adaptor devices)
- Mini-needle low-depth injection technique
- Preclinical animal-model testing
- Dose-sparing intradermal administration
News & Updates
Regulatory clearance reported allowing commercialization in the UK (MHRA).
Exhibitions and presentations at industry conferences to present device results and engage with stakeholders.
Announcement of participation in a multi-partner EUROSTARS project (RABIVA) addressing relevant vaccine delivery topics.
Series of white papers covering intradermal vaccination use cases (e.g., mpox/monkeypox, HPV, veterinary vaccination), dose-sparing, and device rationale.
Multiple posts addressing skin immunology, needle phobia, vaccine dose-sparing, and device applications across human and veterinary health.
Award for a poster presenting preclinical evaluation data on device safety and performance.
Regulatory clearance reported allowing commercialization in the UK (MHRA).
Exhibitions and presentations at industry conferences to present device results and engage with stakeholders.
Announcement of participation in a multi-partner EUROSTARS project (RABIVA) addressing relevant vaccine delivery topics.
Series of white papers covering intradermal vaccination use cases (e.g., mpox/monkeypox, HPV, veterinary vaccination), dose-sparing, and device rationale.
Multiple posts addressing skin immunology, needle phobia, vaccine dose-sparing, and device applications across human and veterinary health.
Award for a poster presenting preclinical evaluation data on device safety and performance.